Impact of SGLT2 Inhibitors on Heart Failure With Reduced Ejection Fraction in Diabetics

Authors

  • Géssica Martins Veiga
  • Mirlene Gonçalves Santos
  • Vinícius Nery Oliveira
  • Renato Philipe de Sousa

Keywords:

SGLT2 inhibitors, Heart Failure with Reduced Ejection Fraction, Type 2 Diabetes Mellitus

Abstract

Objective: Heart failure with reduced ejection fraction (HFrEF) and type 2 Diabetes Mellitus (DM2) are frequently associated chronic conditions, resulting in an unfavorable prognosis and high cardiovascular mortality. This systematic review aims to evaluate the impact of sodium-glucose cotransporter 2 (iSGLT2) inhibitors on HFrEF in patients with DM2. The research was conducted in the PubMed database, covering the period from 2020 to 2025, and followed the PICO strategy for the selection of clinical trials, meta-analyses and systematic reviews. The results of the studies analyzed, including trials with Dapagliflozin, Empagliflozin and Canagliflozin, consistently demonstrated that iSGLT2 significantly reduces the combined outcome of cardiovascular death and hospitalizations for heart failure. In addition to the cardiovascular benefits, improvement in glycemic control and a favorable safety profile were observed. The present review reaffirms the fundamental role of iSGLT2 as an essential therapy in the management of patients with HFrEF and DM2, positively modifying the course of the disease and improving survival and quality of life.

References

Park JJ. Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes. Diabetes & Metabolism Journal. 2021 Mar 31;45(2):146–57.

Butler J, Usman MS, Khan MS, Greene SJ, Friede T, Vaduganathan M, et al. Efficacy and safety of SGLT2 inhibitors in heart failure: systematic review and meta‐analysis. ESC Heart Failure. 2020 Dec;7(6):3298–309.

Yankah RK, Anku EK, Vinay Eligar. Sodium-Glucose Cotransporter-2 Inhibitors and Cardiovascular Protection Among Patients With Type 2 Diabetes Mellitus: A Systematic Review. Journal of diabetes research. 2024 May 11;2024:1–9.

Solomon SD, McMurray JJV, Claggett B. Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. New England Journal of Medicine [Internet]. 2022 Aug 27;387(12). Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa2206286

Blair HA. Dapagliflozin: A Review in Symptomatic Heart Failure with Reduced Ejection Fraction. American Journal of Cardiovascular Drugs. 2021 Oct 15;

Packer M, Anker SD, Butler J, Filippatos G, Ferreira JP, Pocock SJ, et al. Empagliflozin in Patients With Heart Failure, Reduced Ejection Fraction, and Volume Overload: EMPEROR-Reduced Trial. Journal of the American College of Cardiology [Internet]. 2021 Mar 23;77(11):1381–92. Available from: https://pubmed.ncbi.nlm.nih.gov/33736819/

Keller DM, Ahmed N, Tariq H, Walgamage M, Walgamage T, Mohammed A, et al. SGLT2 Inhibitors in Type 2 Diabetes Mellitus and Heart Failure—A Concise Review. Journal of Clinical Medicine. 2022 Mar 8;11(6):1470. Xu B, Li S, Kang B, Zhou J. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Cardiovascular Diabetology [Internet]. 2022 May 25 [cited 2022 Jun 8];21(1). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9134641/

Jhalani NB. Clinical Considerations for Use of SGLT2 Inhibitor Therapy in Patients with Heart Failure and Reduced Ejection Fraction: A Review. Advances in Therapy. 2022 Jun 14;39(8):3472–87.

Omar M, Jensen J, Frederiksen P, Kistorp C, Lars Videbæk, Mikael Kjær Poulsen, et al. Effect of Empagliflozin on Hemodynamics in Patients With Heart Failure and Reduced Ejection Fraction. 2020 Dec 8;76(23):2740–51.

Hundertmark MJ, Agbaje OF, Coleman R, George JT, Grempler R, Holman RR, et al. Design and rationale of the EMPA-VISION trial: investigating the metabolic effects of empagliflozin in patients with heart failure. ESC heart failure [Internet]. 2021 Aug 1 [cited 2024 Mar 13];8(4):2580–90. Available from: https://pubmed.ncbi.nlm.nih.gov/33960149/

Tanaka A, Imai T, Shimabukuro M, Taguchi I, Akira Sezai, Toyoda S, et al. Association between serum insulin levels and heart failure-related parameters in patients with type 2 diabetes and heart failure treated with canagliflozin: a post-hoc analysis of the randomized CANDLE trial. Cardiovascular Diabetology [Internet]. 2022 Aug 8 [cited 2025 Sep 5];21(1). Available from: https://pmc.ncbi.nlm.nih.gov/articles/PMC9358857/#Sec11

Downloads

Published

2026-03-01

How to Cite

Veiga, G. M., Santos, M. G., Oliveira, V. N., & Sousa, R. P. de. (2026). Impact of SGLT2 Inhibitors on Heart Failure With Reduced Ejection Fraction in Diabetics. Revista De Divulgação Científica Sena Aires, 15(Esp.3), 54–59. Retrieved from https://rdcsa.emnuvens.com.br/revista/article/view/1107

Issue

Vol. 15 No. Esp.3 (2026): REVISA-Número Especial- Congresso Interdisciplinar da Área Médica

Section

Literature Review

License

Copyright (c) 2026 Revista de Divulgação Científica Sena Aires

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

  • Atribuição — Você deve dar o crédito apropriado, prover um link para a licença e indicar se mudanças foram feitas. Você deve fazê-lo em qualquer circunstância razoável, mas de nenhuma maneira que sugira que o licenciante apoia você ou o seu uso.

  • Sem restrições adicionais — Você não pode aplicar termos jurídicos ou medidas de caráter tecnológico que restrinjam legalmente outros de fazerem algo que a licença permita.